1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. p38 MAPK
  4. p38γ Isoform

p38γ

 

p38γ Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-10320
    Doramapimod
    Inhibitor 99.98%
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
  • HY-10456
    TAK-715
    Inhibitor 99.89%
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively.
  • HY-108642B
    AMG-548 dihydrochloride
    Inhibitor 99.85%
    AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.
  • HY-108642
    AMG-548
    Inhibitor ≥99.0%
    AMG-548, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.
  • HY-120595
    JNJ-49095397
    Inhibitor
    JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK.
  • HY-147518
    p38-α MAPK-IN-5
    Inhibitor
    p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively.
  • HY-108642A
    AMG-548 hydrochloride
    Inhibitor
    AMG-548 hydrochloride, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.